MRCY enters the week on the back foot — a sharp 5.9% single-day decline on Tuesday cut the stock to $115.83, even as its defense-tech peers absorbed the session with far smaller losses, sharpening the question of whether the move reflects stock-specific pressure or something more structural.
The positioning picture is mild but directionally worth watching. Short interest has crept up to 7.9% of free float — a modest 1.2% rise on the week and about 4.75 million shares net short. That's not an extreme level by itself, but it marks a quiet rebuilding after a 3.4% decline in the month prior, suggesting some bears are cautiously returning. The lending market remains far from stressed: borrow availability is running near 481%, meaning roughly five shares are available for every one currently lent out, and cost to borrow has lifted to 0.53% — a 14% jump on the week, though still firmly in "easy" territory in absolute terms. Options show no unusual hedging pressure. The put/call ratio at 0.56 is barely above its 20-day average of 0.55, with a z-score close to zero, which points to a market neither rushing to hedge nor leaning aggressively bullish.
The divergence with peers is the sharper story. DRS gained 11% on the week. added 7.2%. rose 4.9%. was up nearly 4%. MRCY gave back 5.3%. That's a wide gap for names that carry 54–64% price correlations. The relative weakness isolates MRCY from a broader defense-tech move that was otherwise constructive.
The Street is split on where the stock should be. Analyst consensus puts the mean price target at $101.50 — well below Tuesday's close of $115.83 — which implies the market is already pricing above where most of the sell side is comfortable. Goldman Sachs reiterated its Sell in May, lifting its target to $68, while buy-side supporters at Canaccord and Truist hold targets around $106–$109. The gap between those camps is significant. EPS momentum is a genuine bright spot: the 90-day EPS momentum factor ranks in the 86th percentile, and 12-month forward EPS growth sits in the 83rd. The bull case rests on the 13.1% EBITDA margin recovery and 356% jump in free cash flow reported in fiscal 2025, alongside 31% growth in its core Modules business. Bears point to deteriorating bookings — contracting at nearly a 10% CAGR — and a valuation that still lags defense peers on EBITDA multiples. The EV/EBITDA of roughly 40x has actually compressed modestly on the week, down about 2.3 turns, but remains elevated.
One institutional wrinkle worth noting: JANA Partners has been a consistent seller. The activist fund cut roughly 852,000 shares in the March quarter and its insider-related trading in early March saw the fund shed over 450,000 shares across three sessions near $90–$94. JANA still holds 6.8% of shares outstanding, but its direction of travel has been clearly one-way. BlackRock added 416,000 shares in the June quarter and State Street added 442,000, partially offsetting the JANA outflows, but the backdrop of a known activist reducing exposure is a headwind on sentiment.
The next earnings print is scheduled for August 11. After the May report, the stock jumped 16.7% the following day and extended that gain to 17.6% over the next five sessions — a reminder that MRCY can move sharply on results. How the stock absorbs Tuesday's sell-off over the remaining weeks before that date, and whether short interest continues its quiet rebuild, is the key setup to track into August.
See the live data behind this article on ORTEX.
Open MRCY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
